Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Pioneering Cannabinoid Glaucoma Therapy: SKT-01 represents a novel approach to treating glaucoma by leveraging the therapeutic potential of cannabinoids (THC prodrug) while mitigating psychoactive side effects through targeted ocular delivery.
Advanced Prodrug Platform: Skye's proprietary prodrug technology enhances the bioavailability, targeted delivery, and therapeutic profile of cannabinoids, creating differentiated and potent drug candidates.
Addressing Glaucoma's Unmet Needs: SKT-01 aims to provide a new, potentially more effective and better-tolerated treatment option for patients with glaucoma, a condition with significant unmet needs despite existing therapies.
Risks
Clinical Trial Failure Risk: The company's success heavily relies on the outcomes of its ongoing and future clinical trials for drug candidates, which have a high rate of failure at various stages.
Regulatory Approval Uncertainty Risk: Even with positive clinical trial results, there is no guarantee that Skye Bioscience will obtain the necessary regulatory approvals from agencies like the FDA or EMA to commercialize its product candidates.
Significant Capital Requirements Risk: Developing new pharmaceutical products is extremely costly, and the company will require substantial additional financing to complete clinical trials and pursue commercialization, which may lead to shareholder dilution or an inability to fund operations.
Over a week ago
May 12, 6:37 AM
May 11, 4:11 PM
Mar 10, 4:06 PM
Feb 2, 7:20 AM
Jan 29, 7:20 AM
Jan 12, 7:06 AM
Nov 10, 4:11 PM
Nov 5, 7:45 AM
Oct 6, 12:12 PM
Oct 6, 10:30 AM
Oct 6, 10:19 AM
Oct 6, 7:11 AM
Sep 30, 7:08 AM
Sep 19, 7:03 AM
Sep 4, 7:09 AM
Sep 2, 7:11 AM
Aug 27, 7:10 AM
Aug 14, 4:22 PM
Aug 14, 4:17 PM
No more stories